EMEA-001389-PIP01-12
Key facts
| Active substance |
Deleobuvir
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0240/2013
|
| PIP number |
EMEA-001389-PIP01-12
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of chronic viral hepatitis C
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Boehringer Ingelheim International GmbH
Tel. +49 6132 778271 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|